---
type: earnings-call
company: "DexCom"
ticker: DXCM
quarter: Q3
fiscal_year: 2025
source: Yahoo Finance
---

## Summary
DexCom reported strong Q3 2025 results with 22% revenue growth year-over-year. While the company raised its revenue guidance for the year, it lowered its gross profit margin guidance for 2025 due to scrap dynamics and expedited shipping. The company is focused on expanding CGM access, particularly in the type 2 diabetes market, and addressing G7 sensor performance concerns to improve future performance.

## Guidance
{'Revenue': '4.630 billion to 4.650 billion for the year', 'Gross Profit Margin': 'approximately 61% for 2025', 'Operating Margin': '20% to 21% for 2025', 'Adjusted EBITDA Margin': '29% to 30% for 2025'}

## Strategic Initiatives
['Expanding CGM access, especially in the type 2 diabetes market', 'Improving basal insulin titration and management with DexCom Smart Basal', '15-day sensor launch for revenue growth and margin improvement']

## Risks
['Higher-than-expected scrap rates at manufacturing facilities', 'Deployment challenges with the G7 sensors', 'Supply chain issues requiring expedited shipping', 'Concerns about G7 sensor performance (Bluetooth connectivity, adhesive)']

---
## Transcript
This article first appeared onGuruFocus.

Worldwide Revenue:$1.21 billion, up 22% year-over-year.

US Revenue:$852 million, a 21% increase from the previous year.

International Revenue:$357.4 million, with an 18% organic growth rate.

Gross Profit:$741.3 million, representing 61.3% of revenue.

Operating Expenses:$468.4 million, compared to $413.9 million in Q3 2024.

Operating Income:$272.9 million, or 22.6% of revenue.

Adjusted EBITDA:$368.4 million, or 30.5% of revenue.

Net Income:$242.5 million, or $0.61 per share.

Cash and Cash Equivalents:Over $3.3 billion, with a $400 million increase in the quarter.

Revenue Guidance:Raised to $4.630 billion to $4.650 billion for the year.

Gross Profit Margin Guidance:Lowered to approximately 61% for 2025.

Operating Margin Guidance:20% to 21% for 2025.

Adjusted EBITDA Margin Guidance:29% to 30% for 2025.

Warning! GuruFocus has detected 3 Warning Signs with DXCM.

Is DXCM fairly valued? Test your thesis with our free DCF calculator.

Release Date: October 30, 2025

For the complete transcript of the earnings call, please refer to thefull earnings call transcript.

DexCom Inc (NASDAQ:DXCM) reported a 20% organic revenue growth in the third quarter of 2025 compared to the same period in 2024.

The company has expanded CGM access and solidified its market share in both the US and international markets.

DexCom Inc (NASDAQ:DXCM) has established coverage for nearly 6 million type 2 non-insulin lives in the US, representing about half of the type 2 NIT commercial population.

The introduction of DexCom Smart Basal aims to improve basal insulin titration and management, potentially enhancing adherence and reducing workflow for healthcare providers.

DexCom Inc (NASDAQ:DXCM) achieved its highest quarterly earnings per share in company history, with a net income of $242.5 million or $0.61 per share.

The company's gross profit margin decreased to 61.3% from 63.0% in the third quarter of 2024, impacted by higher-than-expected scrap rates at manufacturing facilities.

There were deployment challenges with the G7 sensors earlier in the year, which affected new customer starts and required additional scrutiny of supplied products.

DexCom Inc (NASDAQ:DXCM) had to invest in expedited shipping due to supply chain issues, impacting overall costs.

The company lowered its 2025 non-GAAP gross profit margin guidance to approximately 61% due to ongoing scrap dynamics.

Despite improvements, there were still some concerns about G7 sensor performance, including Bluetooth connectivity and adhesive issues.

Q: Can you provide any insights into DexCom's growth expectations for 2026?A: Jake Leach, President and Interim CEO, mentioned that while specific guidance for 2026 is not provided, the company anticipates a double-digit growth range based on current coverage landscapes. However, the top end of their range might be slightly below current Street expectations. Opportunities for outperformance exist, particularly with expanded access and innovation pipeline advancements.

Q: Have the issues with the G7 sensor been resolved, and have they impacted new starts or prescribing patterns?A: Jake Leach confirmed that the quality of G7 sensors has improved, addressing earlier deployment challenges. While there was some impact on new starts in Q3, the company remains confident about future performance, with hundreds of thousands of new customer starts in the US and strong international performance.

Q: Where is DexCom seeing the most growth in new patients, and how is the company adapting its market strategy?A: Jereme Sylvain, CFO, noted strong performance across all type 2 markets, including intensive, basal, and non-insulin segments. The company is constantly evaluating its market strategy, focusing on where to call and which channels to market in, to drive growth and find new patients.

Q: What are DexCom's expectations for expanded coverage in 2026, and how will it affect guidance?A: Jake Leach stated that the base case for next year's guidance includes current coverage landscapes. While expanded coverage is anticipated, it will not be included in the base case. Significant wins in coverage will be highlighted as they occur.

Q: Can you discuss the potential impact of the 15-day sensor launch on revenue and margins?A: Jake Leach expressed excitement about the 15-day sensor launch, which is currently in a limited release. The broader launch is expected soon, with significant potential for revenue growth and margin improvement as the product gains traction in the market.

For the complete transcript of the earnings call, please refer to thefull earnings call transcript.
